TD Asset Management
FDMT icon

TD Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

TD Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$685K Buy
+51,482
New +$502K ﹤0.01% 1146
2021
Q2 		– Sell
-27,448
Closed -$1.19M – 1537
2021
Q1 		$1.19M Hold
27,448
– – ﹤0.01% 1231
2020
Q4 		$1.14M Buy
+27,448
New +$1.13M ﹤0.01% 1156

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

TD Asset Management's FDMT Position: Q2 2026 in Review

TD Asset Management opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 51,482 shares worth $685K. The stake represents ﹤0.01% of the portfolio and ranks #1146 among its holdings. This is a return to the name: TD Asset Management previously reported a position in FDMT as recently as Q1 2021.

TD Asset Management first reported a position in FDMT in Q4 2020 and has held it in 3 quarters since. The position peaked at $1.19M in Q1 2021. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • TD Asset Management held 51,482 shares of 4D Molecular Therapeutics worth $685K as of Q2 2026.
  • 4D Molecular Therapeutics was a new TD Asset Management position in Q2 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #1146 holding.
  • TD Asset Management first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 3 quarters since.
  • TD Asset Management's 4D Molecular Therapeutics position peaked at $1.19M in Q1 2021.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.